Preethi Ravindranathan
University of Texas Southwestern Medical Center
21 Papers
12 Citations
Preethi Ravindranathan is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Androgen receptor & Cancer. The author has an hindex of 14, co-authored 20 publications. Previous affiliations of Preethi Ravindranathan include Scott & White Hospital & Baylor University Medical Center.
Chat about Author
Papers
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Matthew J. Schiewer,Jonathan F. Goodwin,Sumin Han,J. Chad Brenner,Michael A. Augello,Jeffry L. Dean,Fengzhi Liu,Jamie L. Planck,Preethi Ravindranathan,Arul M. Chinnaiyan,Peter McCue,Leonard G. Gomella,Ganesh V. Raj,Adam P. Dicker,Jonathan R. Brody,John M. Pascal,Margaret M. Centenera,Lisa M. Butler,Wayne D. Tilley,Felix Y. Feng,Karen E. Knudsen +20 more
TL;DR: It is suggested that the dual functions of PARP-1 can be targeted in human prostate cancer to suppress tumor growth and progression to castration resistance by modulation of the DNA damage response and hormone signaling pathways.
Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
Preethi Ravindranathan,Tae-Kyung Lee,Lin Yang,Lin Yang,Margaret M. Centenera,Lisa M. Butler,Wayne D. Tilley,Jer Tsong Hsieh,Jung-Mo Ahn,Ganesh V. Raj +9 more
TL;DR: The disruption of specific protein-protein interactions involving LXXLL motifs in androgen receptor-coregulator proteins such as PELP1 is reported using a novel, small molecule peptidomimetic (D2) that is stable, non-toxic and efficiently taken up by prostate cancer cells.
Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
TL;DR: Clinical relevance for combining curcumin with chemotherapy to overcome chemoresistance in PDAC is indicated and the re-sensitization of chemoresistant PDAC cells is reported through the inhibition of the PRC2-PVT1-c-Myc axis.
Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer.
TL;DR: In this article, a series of in vitro, in vivo and patient-derived organoid approaches were used to systematically investigate the chemoprotective role of oligomeric proanthocyanidins (OPCs) in colorectal cancer.
A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer
Preethi Ravindranathan,Divya Pasham,Uthra Balaji,Jacob Cardenas,Jinghua Gu,Shusuke Toden,Ajay Goel +6 more
TL;DR: A case is made for the clinical co-administration of curcumin and OPCs as a treatment therapy for patients with colorectal cancer by delineating the cooperative mechanisms of action.